Exact Sciences continues to expand its coverage of Cologuard as Health Care Service Corp (HCSC) and Florida Blue recently updated their medical policies to cover the noninvasive stool DNA screen test for colorectal cancer, the company announced recently.

“We are pleased that Cologuard’s commercial coverage continues to broaden following its inclusion in the recently-updated U.S. Preventive Services Task Force colorectal cancer screening recommendations,” Exact Sciences CEO Kevin Conroy said in a statement. “As health plans continue to update their coverage policies to include Cologuard, an increasing number of people have access to an innovative, non-invasive colorectal cancer screening option.”

According to a release, Cologuard is now available to an additional 80 million people and is now covered for 62 percent of its total target population.

Cologuard is the first and only FDA-approved, noninvasive stool DNA screening test for colorectal cancer.